Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
GLMonte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ Global Select · Currency in USD
$10.48 ▼ -0.36 (-3.32%)
At close: Oct 26, 4:00 PM ET. Market closed.
$10.84 ▲ +0.36 (+3.44%)
After hours: Oct 26, 7:30 PM ET

Summary

Previous Close
$10.84
Open
$10.90
Day's Range
$10.33 – $10.92
52 Week Range
$9.68 – $25.77
Volume
1,226,460
Avg. Volume
1,452,985
Market Cap
$894.08M
Beta (5Y Monthly)
1.37
PE Ratio (TTM)
--
EPS (TTM)
-$1.89
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$24.83

Profile: Monte Rosa Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
173
CEO
Markus Warmuth

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.24 · Revenue est. $33.87M
DateEst.Actual
Aug 6, 2026-$0.38-$0.43Miss
May 7, 2026-$0.28-$0.45Miss
Mar 17, 2026-$0.35-$0.54Miss
Nov 6, 2025-$0.37-$0.33Beat
Aug 7, 2025-$0.38-$0.15Beat
May 8, 2025-$0.00$0.57Beat

Analyst view

Consensus price target
$24.83 ▲ +136.9%
Range $19.00 – $28.00
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Similar stocks

Get free alerts on GLUE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.